The leading pharmaceutical chain company with more than 10,000 stores has been surveyed by more than 50 institutions since the second half of the year!

[Pharmaceutical Industry News] The pharmaceutical and biological industry has always been a key industry for institutional researc.
From the perspective of sub-sectors, listed companies in popular tracks such as medical devices have received more attention from institutions, while pharmacies have received more attention from institution.
rar.
Since the second half of this year, the common people's pharmacy, a leading enterprise with more than 10,000 stores, has been frequently investigated by institution.
On August 1, the People's Pharmacy released the minutes of the institutional investor exchange activity meeting (2027.
The institutions participating in this investigation include Industrial Securities, Northeast Securities, Sinolink Securities, Junheng Capital, Zhenmai Investment, Jinxin Fund, et.
22 investors insid.
On July 1, the company released the minutes of the institutional investor exchange activity meeting (June 2022.
The participating institutions involved CITIC Construction Investment, Guosen Securities, Essence Securities, Harvest Fund, Rongtong Fund, Yinhua Fund, China Merchants Fund, SDIC At least 35 such as UBS Fund and Rongtong Fun.
In the question-and-answer session of investors, the future development prospects of the pharmaceutical retail industry have attracted the attention of institution.
The company said that the increase in the concentration of the pharmaceutical retail industry is still a long-term development tren.
Compared with developed countries, there is still much room for improvement in the concentration of domestic pharmacie.
According to the data of the 2021 annual report of the People's Pharmacy, as of the end of the reporting period, the chain layout network of the People's Pharmacy has covered 20 provincial markets, more than 120 cities above the prefecture level, and more than 590 districts and counties across the countr.
According to the characteristics of different levels of the market, the company adheres to the three-dimensional deep cultivation model of direct sales, spark (mergers and acquisitions), franchises, and alliances, and drives rapid expansion in two-wheel drive of endogenous development and extensional expansio.
On June 26 this year, the 10,000th store of Common People's Pharmacy, Taojiang Taiping Road Store in Yiyang, Hunan officially opened, which means that the number of its stores has officially exceeded 10,000, and Common People has become the first private listing in China with more than 10,000 store.
Chain pharmacie.
The acquisition can be said to be an important measure for the leading pharmaceutical chain companies to staking their land and expanding their territor.
Not only ordinary people, but also leading companies such as Yifeng Pharmacy, Yixintang, and Dashenlin are also accelerating their merger and expansion, striving to enter the "Wandian Era.
.
In the institutional survey, the common people said that they have long adhered to inter-bank acquisitions and focused on existing advantageous market.
At present, the company's acquisitions are divided into equity acquisitions and asset acquisition.
The target of equity acquisition is generally a regional market leader, and it mainly focuses on the competitiveness and profitability of the target company and the synergy effect with the company's existing layou.
For asset acquisition, it mainly focuses on the location and passenger flow of the stor.
After the acquisition, the store will be re-opened after changing the door, which is similar to the opening of a new stor.
In addition, the common people are still actively exploring diversificatio.
The company said that it is currently piloting a diversified pharmacy mode.
By introducing more non-drug varieties, it uses high-frequency non-drug drainage to drive the sales of low-frequency pharmaceutical and health product.
The 2021 annual report shows that the common people achieved operating income of 1696 billion yuan, a year-on-year increase of 138%, and realized a net profit attributable to shareholders of listed companies of 669 million yuan, a year-on-year increase of 75%; after the retrospective adjustment of the new leasing standards, the net profit attributable to shareholders of listed companies Profits actually increased by 110.
In order to release confidence in performance growth, People's Pharmacy also released the 2022 Restricted Stock Incentive Plan (Draft) at the end of Jul.
It plans to issue A-share ordinary shares to the incentive object.
The number of restricted shares to be granted is 1054 million shares, accounting for the current compan.
533% of the total share capita.
Among them, 6727 million shares were granted for the first time, accounting for 807% of the total equity to be granted under the incentive plan, and the grant price was 178 yuan per shar.

The total number of incentive objects to be granted by the incentive plan for the first time is not more than 321, covering the company's senior management, middle management and core backbone.
China National Financial Securities released a research report on August 2, saying that the compound growth rate of net profit attributable to the parent in three years of ordinary people is 117%, and the company's performance growth is more certai.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyon.